BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 24095205)

  • 1. New drugs and targeted treatments in Hodgkin's lymphoma.
    Provencio M; Sánchez A; Sánchez-Beato M
    Cancer Treat Rev; 2014 Apr; 40(3):457-64. PubMed ID: 24095205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microenvironment-related biomarkers and novel targets in classical Hodgkin's lymphoma.
    Carlo-Stella C; Santoro A
    Biomark Med; 2015; 9(8):807-17. PubMed ID: 26223461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel treatment concepts in Hodgkin lymphoma.
    Glimelius I; Diepstra A
    J Intern Med; 2017 Mar; 281(3):247-260. PubMed ID: 27991731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brentuximab vedotin desensitization in a patient with refractory Hodgkin's lymphoma.
    Arora A; Bhatt VR; Liewer S; Armitage JO; Bociek RG
    Eur J Haematol; 2015 Oct; 95(4):361-4. PubMed ID: 25892213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New therapeutic targets and drugs in non-Hodgkin's lymphoma.
    Sawas A; Diefenbach C; O'Connor OA
    Curr Opin Hematol; 2011 Jul; 18(4):280-7. PubMed ID: 21654386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managing Hodgkin lymphoma without chemotherapy: a novel, yet 'welcomed', challenge.
    Kourie HR; Tabchi S; Kattan J
    Future Oncol; 2016 Jun; 12(12):1435-7. PubMed ID: 27117227
    [No Abstract]   [Full Text] [Related]  

  • 7. An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma.
    Apuri S; Sokol L
    Expert Opin Investig Drugs; 2016 Jun; 25(6):687-96. PubMed ID: 26954526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New treatments of malignant lymphoma--a review].
    Mark M; Cerny T
    Ther Umsch; 2010 Oct; 67(10):537-43. PubMed ID: 20886460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel agents in Hodgkin lymphoma.
    Moskowitz AJ
    Curr Oncol Rep; 2012 Oct; 14(5):419-23. PubMed ID: 22706966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hodgkin lymphoma].
    Nagai H
    Nihon Rinsho; 2014 Jun; 72(6):1099-103. PubMed ID: 25016811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Refractory Hodgkin lymphoma.
    von Tresckow B; Engert A
    Curr Opin Oncol; 2013 Sep; 25(5):463-9. PubMed ID: 23942291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An update on emerging drugs for Hodgkin lymphoma.
    von Tresckow B; Diehl V
    Expert Opin Emerg Drugs; 2014 Jun; 19(2):215-24. PubMed ID: 24749769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decision-making in the management of adult classical Hodgkin's lymphoma: determining the optimal treatment.
    Mounier N; Gisselbrecht C
    Expert Rev Hematol; 2015 Apr; 8(2):205-16. PubMed ID: 25634543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of hematopoietic stem cell transplantation in the treatment of relapsed/refractory Hodgkin's lymphoma.
    Sureda A; Pereira MI; Dreger P;
    Curr Opin Oncol; 2012 Nov; 24(6):727-32. PubMed ID: 23079783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New investigational drugs for lymphoma.
    Younes A
    Clin Adv Hematol Oncol; 2009 May; 7(5):308-10. PubMed ID: 19521318
    [No Abstract]   [Full Text] [Related]  

  • 16. Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas.
    Watanabe T
    Expert Opin Investig Drugs; 2010 Sep; 19(9):1113-27. PubMed ID: 20649502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter phase II study of darinaparsin in relapsed or refractory Hodgkin's and non-Hodgkin's lymphoma.
    Hosein PJ; Craig MD; Tallman MS; Boccia RV; Hamilton BL; Lewis JJ; Lossos IS
    Am J Hematol; 2012 Jan; 87(1):111-4. PubMed ID: 22081459
    [No Abstract]   [Full Text] [Related]  

  • 18. Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma.
    Dann EJ; Daugherty CK; Larson RA
    Bone Marrow Transplant; 1997 Sep; 20(5):369-74. PubMed ID: 9339751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Fundamental approaches to the treatment of refractory and relapsed Hodgkin lymphoma].
    Filatova LV; Tarasenkova AA; Semiglazova TIu; Gershanovich ML
    Vopr Onkol; 2012; 58(4):443-53. PubMed ID: 23607197
    [No Abstract]   [Full Text] [Related]  

  • 20. Targeted therapy for thyroid cancer: An updated review of investigational agents.
    Deshpande HA; Gettinger SN; Sosa JA
    Curr Opin Investig Drugs; 2010 Jun; 11(6):661-8. PubMed ID: 20496261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.